Carcinoma, Endometrioid: An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Adenocarcinoma, Clear Cell: An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)Cystadenocarcinoma, Serous: A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.Cystadenocarcinoma, Papillary: An adenocarcinoma in which the tumor elements are arranged as finger-like processes or as a solid spherical nodule projecting from an epithelial surface.Endometrial Hyperplasia: Benign proliferation of the ENDOMETRIUM in the UTERUS. Endometrial hyperplasia is classified by its cytology and glandular tissue. There are simple, complex (adenomatous without atypia), and atypical hyperplasia representing also the ascending risk of becoming malignant.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Adenocarcinoma, Mucinous: An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)Carcinoma in Situ: A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.Mixed Tumor, Mullerian: A tumor, basically a carcinoma with a single sarcoma such as leiomyosarcoma or angiosarcoma or multiple sarcomas of uterine origin. The role of estrogen has been postulated as a possible etiological factor in this tumor. (Holland et al., Cancer Medicine, 3d ed, p1703)Uterine Neoplasms: Tumors or cancer of the UTERUS.Hysterectomy: Excision of the uterus.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Endometriosis: A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Carcinosarcoma: A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Liver Neoplasms: Tumors or cancer of the LIVER.Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Tissue Array Analysis: The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.Carcinoma, Ductal, Breast: An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.Carcinoma, Adenosquamous: A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.PTEN Phosphohydrolase: A lipid phosphatase that acts on phosphatidylinositol-3,4,5-trisphosphate to regulate various SIGNAL TRANSDUCTION PATHWAYS. It modulates CELL GROWTH PROCESSES; CELL MIGRATION; and APOPTOSIS. Mutations in PTEN are associated with COWDEN DISEASE and PROTEUS SYNDROME as well as NEOPLASTIC CELL TRANSFORMATION.Carcinoma, Basal Cell: A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)Neoplasms, Glandular and Epithelial: Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.Cystadenocarcinoma, Mucinous: A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)Dilatation and Curettage: Dilatation of the cervix uteri followed by a scraping of the endometrium with a curette.Endometrium: The mucous membrane lining of the uterine cavity that is hormonally responsive during the MENSTRUAL CYCLE and PREGNANCY. The endometrium undergoes cyclic changes that characterize MENSTRUATION. After successful FERTILIZATION, it serves to sustain the developing embryo.Neoplasm Grading: Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.Neoplasms, Cystic, Mucinous, and Serous: Neoplasms containing cyst-like formations or producing mucin or serum.Ovarian Cysts: General term for CYSTS and cystic diseases of the OVARY.Cell Line, Tumor: A cell line derived from cultured tumor cells.Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.beta Catenin: A multi-functional catenin that participates in CELL ADHESION and nuclear signaling. Beta catenin binds CADHERINS and helps link their cytoplasmic tails to the ACTIN in the CYTOSKELETON via ALPHA CATENIN. It also serves as a transcriptional co-activator and downstream component of WNT PROTEIN-mediated SIGNAL TRANSDUCTION PATHWAYS.Lymphatic Metastasis: Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.Salpingectomy: Excision of one or both of the FALLOPIAN TUBES.Carcinoma, Bronchogenic: Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.Tumor Suppressor Protein p53: Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.Carcinoma, Intraductal, Noninfiltrating: A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.Carcinoma, Adenoid Cystic: Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)Epididymal Secretory Proteins: Proteins secreted by the epididymal epithelium. These proteins are both tissue- and species-specific. They are important molecular agents in the process of sperm maturation.Microsatellite Instability: The occurrence of highly polymorphic mono- and dinucleotide MICROSATELLITE REPEATS in somatic cells. It is a form of genome instability associated with defects in DNA MISMATCH REPAIR.Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)Immunoenzyme Techniques: Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.Carcinoma, Medullary: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Carcinoma, Lobular: A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)Precancerous Conditions: Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.Carcinoma, Neuroendocrine: A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)Urethral Neoplasms: Cancer or tumors of the URETHRA. Benign epithelial tumors of the urethra usually consist of squamous and transitional cells. Primary urethral carcinomas are rare and typically of squamous cells. Urethral carcinoma is the only urological malignancy that is more common in females than in males.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Nasopharyngeal Neoplasms: Tumors or cancer of the NASOPHARYNX.Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Ubiquitin-Conjugating Enzymes: A class of enzymes that form a thioester bond to UBIQUITIN with the assistance of UBIQUITIN-ACTIVATING ENZYMES. They transfer ubiquitin to the LYSINE of a substrate protein with the assistance of UBIQUITIN-PROTEIN LIGASES.Loss of Heterozygosity: The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.Carcinoma, Mucoepidermoid: A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)DNA Mutational Analysis: Biochemical identification of mutational changes in a nucleotide sequence.Mitotic Index: An expression of the number of mitoses found in a stated number of cells.Oligonucleotide Array Sequence Analysis: Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.Mixed Tumor, Mesodermal: A sarcoma of the body of the uterus arising in older women, composed of more than one mesenchymal tissue, especially including striated muscle cells. It is associated with previous pelvic radiation exposure in 20% of patients. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1702)Reverse Transcriptase Polymerase Chain Reaction: A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)Genes, Tumor Suppressor: Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.Kaplan-Meier Estimate: A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Gene Expression Profiling: The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.Carcinoma, Embryonal: A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.Mouth Neoplasms: Tumors or cancer of the MOUTH.Carcinoma, Merkel Cell: A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)Receptors, Progesterone: Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.Carcinoma, Ductal: Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Microsatellite Repeats: A variety of simple repeat sequences that are distributed throughout the GENOME. They are characterized by a short repeat unit of 2-8 basepairs that is repeated up to 100 times. They are also known as short tandem repeats (STRs).CA-125 Antigen: Carbohydrate antigen most commonly seen in tumors of the ovary and occasionally seen in breast, kidney, and gastrointestinal tract tumors and normal tissue. CA 125 is clearly tumor-associated but not tumor-specific.Antigens, Tumor-Associated, Carbohydrate: Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.Adrenocortical Carcinoma: A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.Carcinoma, Verrucous: A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)Carcinoma, Signet Ring Cell: A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.Receptors, Estrogen: Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.Tumor Suppressor Proteins: Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Nuclear Proteins: Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.Chromosomes, Human, Pair 10: A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.Stomach Neoplasms: Tumors or cancer of the STOMACH.Skin Neoplasms: Tumors or cancer of the SKIN.Lymph Node Excision: Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966)Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Case-Control Studies: Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.Gene Expression: The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.Cytoskeletal Proteins: Major constituent of the cytoskeleton found in the cytoplasm of eukaryotic cells. They form a flexible framework for the cell, provide attachment points for organelles and formed bodies, and make communication between parts of the cell possible.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Mice, Nude: Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.Carcinoma, Large Cell: A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)Lymph Nodes: They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.Sex Cord-Gonadal Stromal Tumors: Neoplasms derived from the primitive sex cord or gonadal stromal cells of the embryonic GONADS. They are classified by their presumed histogenesis and differentiation. From the sex cord, there are SERTOLI CELL TUMOR and GRANULOSA CELL TUMOR; from the gonadal stroma, LEYDIG CELL TUMOR and THECOMA. These tumors may be identified in either the OVARY or the TESTIS.Cadherins: Calcium-dependent cell adhesion proteins. They are important in the formation of ADHERENS JUNCTIONS between cells. Cadherins are classified by their distinct immunological and tissue specificities, either by letters (E- for epithelial, N- for neural, and P- for placental cadherins) or by numbers (cadherin-12 or N-cadherin 2 for brain-cadherin). Cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.Transcription Factors: Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.

Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. (1/354)

The primary element in the cAMP signal transduction pathway is the cAMP-dependent protein kinase (PKA). Expression of the RIalpha subunit of type I PKA is elevated in a variety of human tumours and cancer cell lines. The purpose of this study was to assess the prognostic importance of RIalpha expression in patients with ovarian cancer. We have evaluated the expression of RIalpha in a panel of human ovarian tumours (n = 40) and five human ovarian cancer cell lines using quantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blot analysis. The human ovarian cell lines OAW42 and OTN14 express high endogenous levels of RIalpha mRNA and protein (at significantly higher mRNA levels than high tissue expressors, P < 0.05). The ovarian cell line A2780 expresses low endogenous levels of RIalpha mRNA and protein (also at higher mRNA levels than low tissue expressors, P < 0.05). Quantitative RT-PCR revealed no significant difference in RIalpha mRNA expression between different ovarian histological subtypes in this study. No associations were found between RIalpha mRNA expression and differentiation state. RIalpha mRNA expression was significantly associated with tumour stage (P = 0.0036), and this remained significant in univariate analysis (P = 0.0002). A trend emerged between RIalpha mRNA expression levels and overall survival in univariate analysis (P = 0.051), however, by multivariate analysis, stage remained the major determinant of overall survival (P = 0.0001). This study indicates that in ovarian epithelial tumours high RIalpha mRNA expression is associated with advanced stage disease. RIalpha expression may be of predictive value in ovarian cancer and may be associated with dysfunctional signalling pathways in this cancer type.  (+info)

Primary endometrioid carcinoma of fallopian tube. Clinicomorphologic study. (2/354)

Twenty cases of primary Fallopian tube endometrioid carcinoma (PFTEC) are presented in the paper. This accounts for 42.5% of all histologic forms of primary Fallopian tube carcinoma (PFTC) found in our Department. The youngest patient was 38, and the oldest 68 years (mean: 56 years). Seven patients were nulliparas. Only two cases were bilateral. According to FIGO staging, 13 cases were evaluated as stage I, 4 as II, and 3 as stage III. Due to the histologic grading, 8 tumors were classified as well, 7 as moderately, and 5 as poorly differentiated. In the time of preparation of the manuscript, 12 women were still alive, 2 of them with recurrent disease. The follow-up of patients without recurrence ranged from 4 to 120 months (median: 63). Eight patients had died (survival time: from 4 to 65 months; median: 26). Metastases were found in 8 patients, especially to ovaries. In 14/20 cases of PFTEC various forms of tubal wall invasion were observed. Blood or lymphatic vessels involvement was found in 9 patients. Six of them had died and one is alive with the symptoms of disease. Immunohistochemical detection of the mutant form of p53 protein and oncogene product, c-erbB-2, was studied in 17 cases. Nine patients exhibited simultaneous p53 protein accumulation and c-erbB-2 expression. 2/9 of these patients are alive with recurrent tumors and 4/9 died. Endometrioid carcinoma of the Fallopian tube can be characterized by a tendency to superficial invasion of tubal wall and in a half of the cases by invasion of vessels. The majority of these tumors were diagnosed at an early stage tumors.  (+info)

Clear cell carcinoma arising in a Cesarean section scar endometriosis: a case report. (3/354)

Endometriosis of a surgical scar is rare and occurs mainly when a hysterectomy or Cesarean section was performed. We describe a 54-year-old woman with a large suprapubic mass as a definite case of a endomerioid carcinoma developing within the scar endometriosis following Cesarean section. Scar endometriosis, as well as endometriosis at other sites, can turn malignant. Endometrioid carcinoma is the most common histological pattern of malignant tumor arising in endometriosis. But clear cell carcinoma is very unusual. A case of primary clear cell carcinoma in endometriosis of a Cesarean section scar is described. To the best of our knowledge, this is the first documented case of endomerioid carcinoma developing within the scar endometriosis in Korea.  (+info)

Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: correlation with up-regulation in epithelial ovarian cancer. (4/354)

Abnormalities in the function of receptor tyrosine kinases (RTKs) have been demonstrated to be important in the pathogenesis of cancer. H-Ryk, a new member of the RTK family, is an unusual RTK in that it is catalytically inactive because of amino acid substitutions of conserved residues in the catalytic domain. We show by immunohistochemistry that it is expressed in the epithelium, stroma, and blood vessels of normal tissues. Evaluation of a panel of 33 primary ovarian tumors (2 benign, 8 borderline, and 23 malignant) was performed. H-Ryk was overexpressed in borderline and malignant ovarian tumors. In serous and clear cell subtypes, there was increased expression in the epithelium, stroma, and blood vessels. Consistent with this observation, overexpression of H-Ryk in the mouse fibroblast cell line NIH3T3 induces anchorage-independent growth and tumorigenicity in nude mice. This implies that overexpression of the receptor can be transforming and may therefore be significant in the pathogenesis of ovarian cancer.  (+info)

beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome. (5/354)

The immunohistochemical expression pattern of beta-catenin has been correlated with beta-catenin gene mutations, clinicopathological features, and disease outcome in 69 stage I and II ovarian carcinomas. beta-Catenin expression was localized in the nuclei, in addition to the cytoplasm and membrane, in 11 tumors (16%): nine endometrioid carcinomas with widespread nuclear expression and two serous carcinomas with focal nuclear expression. The remaining 58 carcinomas (84%) only had membranous beta-catenin expression. All but one of the endometrioid carcinomas with nuclear beta-catenin expression had considerable squamous metaplasia, and five of these cases had large areas of endometrioid tumor of low malignant potential. In addition, beta-catenin nuclear expression was observed in atypical epithelial cells in endometriotic glands adjacent to an endometrioid carcinoma. Sequencing was performed on 25 tumors and corresponding normal tissue: all 13 endometrioid tumors as well as 12 carcinomas of other histological types (four serous, two clear cell, two mucinous, and two mixed). There were oncogenic mutations in the phosphorylation sequence for GSK-3beta in exon 3 of the beta-catenin gene in seven endometrioid carcinomas with beta-catenin nuclear expression. Three mutations affected codon 32 (D32G, D32Y, and D32Y), one affected codon 33 (S33C), two affected codon 37 (S37C and S37F), and one affected codon 41 (T41A). No mutations were observed in the other 18 carcinomas analyzed, comprising two endometrioid and two serous carcinomas with beta-catenin nuclear expression, and 14 carcinomas of different histological types with only membranous expression. In the univariate and multivariate survival analyses, beta-catenin nuclear expression was selected as an indicator of good prognosis, because no patient whose tumor expressed beta-catenin in the nuclei showed relapses or died, in contrast to the 19 relapses and deaths among patients with tumors that only had beta-catenin membranous expression, including three of the four patients with endometrioid carcinomas. Oncogenic beta-catenin mutation is characteristic of a group of endometrioid carcinomas with a good prognosis, most of which originate from previous benign or borderline lesions. Endometrioid carcinomas with exclusively membranous expression of beta-catenin seem to represent a different subgroup of carcinomas that probably have a worse prognosis. In early-stage ovarian cancer, determination of the beta-catenin expression pattern could prove to be a useful marker for selecting low-risk patients.  (+info)

Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas*. (6/354)

Most of the ovarian cancers originate from the ovarian surface epithelium derived from the coelomic mesothelium. The Met proto-oncogene encodes a transmembrane tyrosine kinase receptor (Met) that has the capacity to regulate cell proliferation and differentation and it is activated by hepatocyte growth factor. Trisomy of chromosome 7 and Met protein overexpression have been were observed in ovarian carcinomas, the papillary renal cancers and other solid tumors. Frequent mutations of Met proto-oncogene have been found in hereditary papillary renal cancer (HPRC) and most of the mutations are located in the tyrosine kinase domain. The aim of this study to perform a mutation analysis of exons 17 19 of Met proto-oncogene in epithelial ovarian tumors (EOTs). We have examined 24 tumor samples from patients, operated with EOTs. Mutation was detected in exon 18 in only one sample of 24 EOTs. Our results indicate that mutations located in the Met proto-oncogene is not a common event in EOT. It is not clear whether the mutation plays a role in the tumorigenesis or progression of EOT or not.  (+info)

Hormone replacement therapy and risk of epithelial ovarian cancer. (7/354)

It has been suggested that oestrogen replacement therapy is associated with risk of epithelial ovarian cancer of the endometrioid type. Using data from an Australian population-based case-control study, the relation between unopposed oestrogen replacement therapy and epithelial ovarian cancer, both overall and according to histological type, was examined. A total of 793 eligible incident cases of epithelial ovarian cancer diagnosed from 1990 to 1993 among women living in Queensland, New South Wales and Victoria were identified. These were compared with 855 eligible female controls selected at random from the electoral roll, stratified by age and geographic region. Trained interviewers administered standard questionnaires to obtain detailed reproductive and contraceptive histories, as well as details about hormone replacement therapy and pelvic operations. No clear associations were observed between use of hormone replacement therapy overall and risk of ovarian cancer. Unopposed oestrogen replacement therapy was, however, associated with a significant increase in risk of endometrioid or clear cell epithelial ovarian tumours (odds ratio (OR) 2.56; 95% confidence interval (CI) 1.32-4.94). In addition, the risk associated with oestrogen replacement therapy was much larger in women with an intact genital tract (OR 3.00; 95% CI 1.54-5.85) than in those with a history of either hysterectomy or tubal ligation. Post-menopausal oestrogen replacement therapy may, therefore, be a risk factor associated with endometrioid and clear cell tumours in particular. Additionally, the risk may be increased predominantly in women with an intact genital tract. These associations could reflect a possible role of endometriosis in the development of endometrioid or clear cell ovarian tumours.  (+info)

A case-control study of galactose consumption and metabolism in relation to ovarian cancer. (8/354)

Consumption or metabolism of dairy sugar and ovarian cancer have been linked based on evidence that galactose may be toxic to ovarian germ cells and that ovarian cancer is induced in animals by depletion of oocytes. We assessed consumption of dairy products and obtained blood for biochemical and molecular genetic assessment of galactose metabolism in 563 women with newly diagnosed epithelial ovarian cancer and 523 control women selected either by random digit dialing or through lists of residents in eastern Massachusetts and New Hampshire. We observed no significant differences between cases and controls in usual consumption of various types of dairy products or total daily lactose (the principal source of galactose in the diet); nor did we find that RBC activity of either galactose-1-phosphate uridyl transferase (GALT) or galactokinase differed. The mean (and SE) activity of uridine diphospho-galactose 4'-epimerase (in micromoles per hour per gram of hemoglobin) was, however, significantly lower (P < 0.005) in cases compared with controls, 20.32 (0.31) versus 21.64 (0.36). Ovarian cancer cases were also more likely to carry the N314D polymorphism of the GALT gene, generally predisposing to lower GALT activity. The difference was most evident for endometrioid and clear cell types of ovarian cancer, in which 3.9% of cases were found to be homozygous for N314D compared with 0.4% of controls, yielding an odds ratio and 95% confidence interval of 14.17 (2.62-76.60). We conclude that, whereas adult consumption of lactose carries no clear risk for the disease, certain genetic or biochemical features of galactose metabolism may influence disease risk for particular types of ovarian cancer.  (+info)

*Endometrioid tumor

In 40% of cases, endometrioid tumors are found bilaterally. Endometrioid carcinoma can also arise in the endometrium. Grades 1 ... Endometrioid tumors are a class of tumor characterized by a resemblance to endometrium/ endometrial carcinoma, and over a third ... Carcinoma, Endometrioid at the US National Library of Medicine Medical Subject Headings (MeSH) "ACS :: What Is Endometrial ... ISBN 0-7216-0187-1. Mulvany NJ, Allen DG (January 2008). "Combined large cell neuroendocrine and endometrioid carcinoma of the ...

*Uterus-like mass

Rahilly MA, Al-Nafussi A (1991). Uterus-like mass of the ovary associated with endometrioid carcinoma. Histopathology 18:549- ... ULM has also been reported associated to endometrial carcinoma and breast cancer. A clonal chromosome deletion 2p21 was found ...

*Endometrial cancer

Papillary serous carcinoma, clear cell carcinoma, and endometrioid carcinoma are the subtypes at the highest risk of recurrence ... Histologically, TCCE resembles endometrioid carcinoma and is distinct from other transitional cell carcinomas. In contrast to ... Some endometrioid adenocarcinomas have foci of mucinous carcinoma. The genetic mutations most commonly associated with ... The most frequent type of endometrial cancer is endometrioid carcinoma, which accounts for more than 80% of cases. Endometrial ...

*Endometrial intraepithelial neoplasia

Risk factors for development of EIN and the endometrioid type of endometrial carcinoma include exposure to estrogens without ... a precursor lesion to uterine endometrioid carcinoma". Cancer Res. 58 (15): 3254-8. PMID 9699651. Mutter GL, Boynton KA, Faquin ... Some cases of EIN are first detected as residual premalignant disease in women who already have carcinoma, whereas other EIN ... Hecht JL, Ince TA, Baak JP, Baker HE, Ogden MW, Mutter GL (March 2005). "Prediction of endometrial carcinoma by subjective ...

*High-grade serous carcinoma

Distinction of HGSC from high-grade endometrioid carcinoma is not always possible. The progression of HGSC may also be ... Technically a 'serous carcinoma' can occur anywhere on these membranes, but high-grade serous carcinoma is generally limited to ... "TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting ... High-grade serous carcinoma (HGSC) is a type of tumour that arises from the serous epithelial layer in the abdominopelvic ...

*Surface epithelial-stromal tumor

15-30% of endometrioid carcinomas occur in individuals with carcinoma of the endometrium, and these patients have a better ... Endometrioid tumors account for approximately 20% of all ovarian cancers and are mostly malignant (endometroid carcinomas). ... Bakhru, Arvind; Liu, J. Rebecca; Lagstein, Amir (2012). "A case of small cell carcinoma of the ovary hypercalcemic variant in a ... epithelial cells with abundant clear cytoplasm and may be seen in association with endometriosis or endometrioid carcinoma of ...

*Tamer Seckin

... is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma." ...

*ASRGL1

"Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma". ...

*WFDC2

... is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas". Cancer Res. 65 (6): 2162-9. ... protein is a biomarker for ovarian carcinoma". Cancer Res. 63 (13): 3695-700. PMID 12839961. Drapkin R, von Horsten HH, Lin Y, ... "Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas". ... Protein Is a Biomarker for Ovarian Carcinoma". Cancer Research. 63 (13): 3695-3700. PMID 12839961. Retrieved 2012-11-28. ...

*List of MeSH codes (C04)

... carcinoma, endometrioid MeSH C04.557.470.200.025.255 --- carcinoma, hepatocellular MeSH C04.557.470.200.025.275 --- carcinoma, ... carcinoma, ehrlich tumor MeSH C04.557.470.200.220 --- carcinoma, giant cell MeSH C04.557.470.200.240 --- carcinoma in situ MeSH ... carcinoma, krebs 2 MeSH C04.557.470.200.260 --- carcinoma, large cell MeSH C04.557.470.200.280 --- carcinoma, lewis lung MeSH ... carcinoma, acinar cell MeSH C04.557.470.200.025.220 --- carcinoma, adenoid cystic MeSH C04.557.470.200.025.232 --- carcinoma, ...

*List of MeSH codes (C13)

... carcinoma, endometrioid MeSH C13.371.056.630.705.398 --- granulosa cell tumor MeSH C13.371.056.630.705.464 --- luteoma MeSH ... carcinoma, endometrioid MeSH C13.371.820.800.418.685.398 --- granulosa cell tumor MeSH C13.371.820.800.418.685.464 --- luteoma ... carcinoma, endometrioid MeSH C13.371.820.800.418.875.200.374 --- endometrial stromal tumors MeSH C13.371.820.800.418.875. ... carcinoma, renal cell MeSH C13.371.820.800.820.535.585 --- wilms tumor MeSH C13.371.820.800.820.535.585.220 --- denys-drash ...

*List of MeSH codes (C19)

... carcinoma, endometrioid MeSH C19.391.630.705.398 --- granulosa cell tumor MeSH C19.391.630.705.464 --- luteoma MeSH C19.391. ... carcinoma, islet cell MeSH C19.344.421.500.124 --- gastrinoma MeSH C19.344.421.500.249 --- glucagonoma MeSH C19.344.421.500.500 ... adrenocortical carcinoma MeSH C19.053.347.500 --- adrenal cortex neoplasms MeSH C19.053.347.500.500 --- adrenocortical adenoma ... adrenocortical carcinoma MeSH C19.344.400.500 --- multiple endocrine neoplasia type 1 MeSH C19.344.400.505 --- multiple ...

*Squamous metaplasia

... endometrioid endometrial carcinoma). Metaplasia Dysplasia Barrett esophagus - a columnar cell metaplasia of squamous epithelium ...

*Membrane progesterone receptor

Notably, the expression of mPRγ was significantly higher in endometrioid and clear cell carcinomas, which are closely related ... and carcinomas: while mPRα is expressed at significantly higher levels than the others, an increased expression of mPRβ has ... been noticed in mucinous carcinomas when compared to the other tumor types and normal tissues. ...

*Ovarian cancer

Though mixed carcinomas can have any combination of cell types, mixed ovarian cancers are typically serous/endometrioid or ... Type I cancers are of low histological grade, and include endometrioid, mucinous, and clear-cell carcinomas. Type II cancers ... More typically, ovarian squamous cell carcinomas are cervical metastases, areas of differentiation in an endometrioid tumor, or ... There are five main subtypes of ovarian carcinoma, of which high-grade serous carcinoma is the most common. These tumors are ...

*Testicular cancer

Tumors of ovarian epithelial types Serous tumor of borderline malignancy Serous carcinoma Well differentiated endometrioid ... Embryonal carcinoma and teratoma Teratoma and seminoma Choriocarcinoma and teratoma.embryonal carcinoma Others Sex cord/Gonadal ... carcinoma in situ) Specified types Tumors of one histologic type (pure forms) Seminoma Variant - Seminoma with ... Brenner tumor Nephroblastoma Paraganglioma Haematopoietic tumors Tumours of collecting ducts and rete Adenoma Carcinoma Tumors ...

*Meigs' syndrome

... endometrioid, or clear cell carcinoma, Brenner tumor, granulosa cell tumor, stromal tumor, dysgerminoma, fibroma, or metastatic ... "A case of Meigs syndrome mimicking metastatic breast carcinoma". World J Surg Oncol. 7: 10. doi:10.1186/1477-7819-7-10. PMC ...

*Uterine clear-cell carcinoma

"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers ... Uterine clear-cell carcinoma is staged like other forms of endometrial carcinoma at time of surgery using the International ... Uterine clear-cell carcinoma (CC) is a rare form of endometrial cancer with distinct morphological features on pathology; it is ... Like uterine papillary serous carcinoma CC does not develop from endometrial hyperplasia and is not hormone sensitive, rather ...

*Uterine serous carcinoma

Unlike the more common low-grade endometrioid endometrial adenocarcinoma, USC does not develop from endometrial hyperplasia and ... Uterine serous carcinoma (USC), also known as uterine papillary serous carcinoma (UPSC) and uterine serous adenocarcinoma, is ... UPSC is staged like other forms of endometrial carcinoma at time of surgery using the FIGO cancer staging system. Stage IA: ... Histopathologically, uterine serous carcinomas is typically characterized by (1) nipple-shaped structures (papillae) with ...

*Uterine cancer

... as well as the more aggressive uterine papillary serous carcinoma and uterine clear-cell carcinoma. Endometrial stromal ... These include the common and readily treatable well-differentiated endometrioid adenocarcinoma, ... carcinosarcoma behaves similar to a high grade carcinoma, and it is felt to be of epithelial origin rather than true sarcoma. ... Endometrial carcinomas originate from cells in the glands of the endometrium (uterine lining). ...

*MTA3

... is overexpressed in non-small cell lung cancer and human placenta and chorionic carcinoma cells. In breast cancer, loss of ... For example, MTA3 expression is downregulated in breast cancer and endometrioid adenocarcinomas. ... "The metastasis-associated genes MTA1 and MTA3 are abundantly expressed in human placenta and chorionic carcinoma cells". ...

*Diablo homolog

... renal cell carcinoma, testicular germ cell tumors, colorectal cancer, lung cancer, bladder cancer, endometrioid endometrial ... So far, SMAC overexpression has been observed to oppose cancer progression in head and neck squamous cell carcinoma, ... December 2010). "Prognostic significance of smac/DIABLO in endometrioid endometrial cancer". Folia Histochemica Et ... "Expression of Smac/DIABLO in ovarian carcinoma cells induces apoptosis via a caspase-9-mediated pathway". Experimental Cell ...

*Ovarian tumor

It includes serous tumour, endometrioid tumor, and mucinous tumour. They can be benign (cystadenoma) or malignant ( ... cystadenocarcinoma). Less common tumors are malignant Brenner tumor and transitional cell carcinoma of the ovary. Sex cord- ...

*Mixed Müllerian tumor

Carcinoma is confined to the corpus uteri itself. Stage II. Carcinoma involves the corpus and the cervix. Stage III. Carcinoma ... On histology, the tumors consist of adenocarcinoma (endometrioid, serous or clear cell) mixed with the malignant mesenchymal ( ... Carcinoma extends outside the true pelvis or involves the mucosa of the bladder or the rectum. Siegal GP, Chhieng DC (2005). ... As with endometrial carcinomas, the prognosis is influenced by the grade and type of the adenocarcinoma, being poorest with ...

*Fetal adenocarcinoma

A case of combined small cell lung carcinoma featuring components of FA and cells resembling those from carcinoid tumor has ... Mardini G, Pai U, Chavez AM, Tomashefski JF (March 1994). "Endobronchial adenocarcinoma with endometrioid features and ... June 1996). "p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas". Hum. Pathol. 27 (6): 542-6. doi: ... November 2008). "[Clinicopathologic study of pulmonary adenocarcinoma with features of bronchioloalveolar carcinoma]". Zhonghua ...

*Mir-449 microRNA precursor family

Wu, W.; Lin, Z.; Zhuang, Z.; Liang, X. (2009). "Expression profile of mammalian microRNAs in endometrioid adenocarcinoma". ... "Histone Deacetylases Activate Hepatocyte Growth Factor Signaling by Repressing MicroRNA-449 in Hepatocellular Carcinoma Cells ...
Endometrioid tumors are a class of tumor characterized by a resemblance to endometrium/ endometrial carcinoma, and over a third of cases have focal squamous differentiation. They are part of the surface epithelial tumor group of ovarian neoplasms (10-20% of which are the endometrioid type). Benign and borderline variants are rare, as the majority are malignant. There is an association with endometriosis and concurrent primary endometrial carcinoma (endometrial cancer). On gross pathological examination, the tumor is cystic and may be solid and some arise in cystic endometriosis. In 40% of cases, endometrioid tumors are found bilaterally. Endometrioid carcinoma can also arise in the endometrium. Grades 1 and 2 are considered "type 1" endometrial cancer, while grade 3 is considered "type 2". Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN gene mutation profiles. PTEN mutations are more frequent in low-grade endometrial endometrioid carcinomas (67%) compared with ...
Endometrial cancer is one of the most common malignancies of the reproductive female tract, with endometrioid endometrial cancer being the most frequent type. Despite the relatively favourable prognosis in cases of endometrial cancer, there is a necessity to evaluate clinical and prognostic utility of new molecular markers. MiRNAs are small, non-coding RNA molecules that take part in RNA silencing and post-transcriptional regulation of gene expression. Altered expression of miRNAs may be associated with cancer initiation, progression and metastatic capabilities. MiRNA-205 seems to be one of the key regulators of gene expression in endometrial cancer. In this study, we investigated clinical and prognostic role of miRNA-205 in endometrioid endometrial cancer. After total RNA extraction from 100 archival formalin-fixed paraffin-embedded tissues, real-time quantitative RT-PCR was used to define miRNA-205 expression levels. The aim of the study was to evaluate miRNA-205 expression levels in regard to
OBJECTIVE We previously described vascular invasion-associated changes, defined as the presence of vascular invasion or perivascular lymphocytic infiltrates, as key prognostic indicators in stage I endometrioid carcinoma. The current study was undertaken to examine the prognostic value of HER-2/neu expression in relation to other factors, including vascular invasion-associated changes, in surgical stage I endometrioid carcinoma. STUDY DESIGN Seventy-one patients with surgical stage I endometrioid carcinoma treated by hysterectomy and followed up were randomly chosen for retrospective analysis of prognostic indicators including standard clincopathologic features, deoxyribonucleic acid ploidy, and HER-2/neu expression. The latter was examined by an objective computerized quantitative immunohistochemical system. RESULTS By univariate analysis many factors were found to correlate with outcome, including age, tumor grade, depth of invasion, ploidy, HER-2/neu expression, and vascular invasion-associated
TY - JOUR. T1 - Description of an endometrioid ovarian cancer cell line. AU - Giancotti, Francesca R.. AU - Dorsett, Brent H.. AU - Weaver, Scott. AU - Bharathur, Rajendra. AU - Ioachim, Harry L.. AU - Barber, Hugh R K. PY - 1989. Y1 - 1989. N2 - A human cell line, designated L-1, has been established from the ascites of an untreated patient with stage IV (FIGO) endometrioid ovarian cancer. This cell line initially grew uninterrupted for 6 months without fibroblast contamination and contact inhibition, and has been subcultured weekly for the past 7 years. L-1 does not contain steroid hormone receptors nor does it demonstrate the presence of oncofetal antigens by immunohistochemical techniques. The doubling time of L-1 is 11.8 hr. Flow cytometric analysis reveals an aneuploid DNA peak, and an abnormal karyotype demonstrates hyperdiploidy, translocations, and deletions. Morphology, growth patterns, cytogenetic analysis, and other features of L-1 are characterized.. AB - A human cell line, ...
Devor EJ, Miecznikowski J, Schickling BM, Gonzalez-Bosquet J, Lankes HA, Thaker P, Argenta PA, Pearl ML, Zweizig SL, Mannel RS, Brown A, Ramirez NC, Ioffe OB, Park KJ, Creasman WT, Birrer MJ, Mutch D, Leslie KK. Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 12; 147(3):648-653 ...
TY - JOUR. T1 - p53 Overexpression and bcl-2 persistence in endometrial carcinoma. T2 - Comparison of papillary serous and endometrioid subtypes. AU - Zheng, Wenxin -. AU - Cao, Peiqin. AU - Zheng, Mei. AU - Kramer, Elmer E.. AU - Godwin, Thomas A.. PY - 1996/5. Y1 - 1996/5. N2 - Forty-two cases, including 21 uterine papillary serous carcinomas (UPSC) and 21 age-, nuclear-grade-, and clinical-stage-matched uterine endometrioid carcinomas (UEC), were studied immunohistochemically for p53 and bcl-2 in archival paraffin-embedded tissue. Compared to UEC (28.6% positive), UPSC (71.4% positive) had a significantly higher frequency of p53 overexpression (P = 0.005); furthermore, in a clinical-stage-matched fashion, a higher frequency of p53 overexpression was found in early-stage cases (P = 0.032), but not in late-stage cases. In a nuclear-grade-matched comparison, no statistical difference in p53 overexpression was identified between the two subtypes, although UPSC had stronger p53 immunoreactivity ...
This randomized phase II trial studies how well medroxyprogesterone acetate with or without entinostat before surgery works in treating patients with endometrioid endometrial cancer. Medroxyprogesterone acetate is a progesterone, a hormone produced by body normally. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Given medroxyprogesterone acetate with or without entinostat may work better in treating patients with endometrioid endometrial cancer.. ...
malissatench - Patient: Endometrial (Uterine) Cancer > Endometrioid Adenocarcinoma > Poorly Differentiated Carcinoma Patient Info: Receiving hospice or palliative care, Diagnosed: about 10 years ago, Female, Age: 33
ProScis uterus tissue slide Endometrioid Adenocarcinoma can be used with any antibody shown to be effective in formalin-fixed tissue using a standard immunostaining protocol.
5219 Insulin growth factor binding protein-3 (IGFBP-3) has been postulated to be a mediator of growth suppression signal. In our previous study, IGFBP-3 was found as an invasion suppressor gene in ovarian endometrioid carcinoma (EC) (Oncogene 2007, on line). Since promoter methylation can silence gene expression, we investigated whether hypermethylation of the IGFBP-3 promoter is involved in the loss of IGFBP-3 expression in ovarian EC. By methylation-specific PCR assay, IGFBP-3 promoter was found methylated in the higher invasive ovarian cancer cell line OVTW59-P4, compared with the lower invasive P0 cell line. After treatment with DNA methyltransferase inhibitor 5-aza-2-deoxycytidine, P4 showed restoration of IGFBP-3 expression. Methylation status correlated with IGFBP-3 mRNA and protein levels. By bisulfite genomic DNA sequencing, the hyprermethylated CpG sites were found focused at the -210, -206, -183 and -179 sites of p53 consensus binding sequence in IGFBP-3 promoter region. A luciferase ...
miRNAs have been implicated in inflammation, fibrosis, EMT and various types of cancers, such as oral cancer. Some miRNA families have gained attention for their clear function in tissue fibrosis. miR-30c has been reported to be a tumor suppressor in endometrial cancer (14) and to act as an independent predictor for the clinical benefit of tamoxifen therapy in patients with advanced breast cancer (15). A previous study showed that miR-206 overexpression inhibited estrogen receptor-α-dependent proliferation, impaired invasiveness and induced cell cycle arrest of estrogen receptor-α-positive endometrial endometrioid adenocarcinoma cell lines (16). miR-203 has previously been shown to play an important role in epithelial cell biology (17). miR-203 was differentially regulated in gingival epithelial cells in the presence of P. gingivalis. Silencing of miR-203 diminished the activation of signal transducer and activator of transcription 3 (Stat3), suggesting that alterations in miRNAs modulate ...
4813 The Wnt signaling pathway is deregulated in nearly half of ovarian endometrioid adenocarcinomas (OEAs), usually as a consequence of activating mutations in CTNNB1, the gene encoding β-catenin. Presumably, Wnt/β-catenin pathway defects contribute to OEA pathogenesis via activation of β-catenin/TCF transcriptional target genes, many of which remain unknown. We employed Affymetrix U133A oligonucleotide microarrays to compare gene expression in OEAs with (n = 13) and without (n = 18) β-catenin defects as a strategy for identifying novel β-catenin/TCF targets. Expression of Wnt-inhibitory factor-1 (WIF-1) transcripts was approximately 12-fold higher in OEAs with demonstrable β-catenin defects compared to OEAs with intact β-catenin regulation (p , 0.0001). WIF-1 expression was also increased in rat kidney epithelial cells (RK3E) neoplastically transformed by mutant β-catenin. Rapid induction of WIF-1 expression was observed following 4-hydoxy-tamoxifen-mediated activation of a chimeric ...
OBJECTIVE The purpose of this study was to evaluate the role of surgical staging in patients with grade 1 endometrioid uterine cancer. STUDY DESIGN Data were extracted from Surveillance, Epidemiology, and End Results Program from 1988 to 2001. Kaplan-Meier and Cox proportional hazards analyses were used to determine predictors for disease-specific survival. RESULTS Twelve thousand seven hundred and twelve women were reported with endometrioid carcinoma, including 3867 with grade 1 disease, of which 25.5% had stage IC or more advanced disease, 15.4% with disease extending beyond the uterine corpus, 7.3% with extrauterine metastases, and 3.3% with lymph node metastases. On multivariate analysis, younger age and earlier stage remained as significant prognostic factors for improved survival. CONCLUSION Since grade 1 endometrioid uterine cancers have a 15.4% risk of extrauterine spread, a complete surgical staging procedure is recommended when clinically feasible. Younger age and earlier stage are
Currently, uveal melanoma is not considered within the Lynch syndrome tumor spectrum. However, there are studies suggesting a contribution of microsatellite instability in sporadic uveal melanoma tumorigenesis. We report a 45-year-old woman who was referred for genetic counseling due to a family history of Lynch syndrome caused by a MLH1 mutation. She originally underwent enucleation (removal) of the right eye secondary to a uveal spindle cell melanoma diagnosed at age 25. The tumor recurred 22 years later presenting as an ovarian metastasis and concurrently a microscopic endometrial endometrioid carcinoma, grade 1/3 was diagnosed. Subsequent studies highlighted that the uveal melanoma showed high microsatellite instability and loss of MLH1 and PMS2 protein expression, with no MLH1 promoter methylation or BRAF mutation. Additionally, a GNAQ mutation was found. We conclude that our patients uveal melanoma is most likely related to MLH1 germline mutation and thus Lynch syndrome related. To the ...
Hyperactivation of the canonical Wnt/β-catenin pathway, caused by mutations in such components as β-catenin and APC, is one of the most frequent signaling abnormalities in several human cancers including colorectal carcinomas (15), melanomas (16), hepatoblastomas (17), medulloblastomas (18), prostatic carcinomas (19), and uterine and ovarian endometrioid adenocarcinomas (10, 20-22). In breast cancer, however, evidence of comparable mutations is surprisingly lacking (23). In contrast, there is strong evidence, based on immunohistochemical analyses, that the Wnt/β-catenin pathway is activated (23-25). Importantly, aberrant β-catenin expression in breast cancer is associated with poor clinical outcome (23-26). Metaplastic carcinomas have never been analyzed for Wnt pathway gene mutations.. Because breast carcinoma arises from glandular epithelium, it usually exhibits the features of an adenocarcinoma. However, in some cases, part or all of the neoplastic cells differentiate into a nonglandular ...
This is a multi-center, open-label, randomized, parallel group two-stage phase 1 study with a phase 2 expansion component in pts with recurrent or metastatic APRpos uterine endometrioid adenocarcinoma. Stage 1: Six dose cohorts, 5 using the extended release tablet (ER) formulation (10 mg BID, 20 mg BID, 30 mg BID, 40 mg BID, 50 mg BID) and 1 using the immediate-release (IR) tablet formulation 100 mg QD will be randomized in parallel. After enrollment of 36 patients in Stage 1, a dose of 50 mg BID was determined to be the RP2D. Stage 2: An additional 10 patients with recurrent or metastatic APRpos uterine endometrioid adenocarcinoma (Stage 2a) will be enrolled at the RP2D. Based on the response in Stage 2a, the cohort will be further expanded by up to 19 more patients to a total of 29 patients to confirm the efficacy and safety profile of onapristone in this selected patient population (Stage 2b ...
臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。. To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of "NTU Repository" with "Academic Hub" to form NTU Scholars.. ...
Synchronous endometrial and ovarian (SEO) carcinomas involve endometrioid neoplasms in both the ovary and uterus at the time of diagnosis. Patients were traditionally classified as having independent primary SEO lesions or as having metastatic endometrioid carcinoma. Recent studies have supported that SEO tumors result from the dissemination of cells from one organ site to another. However, whether this can be considered a "metastasis" or "dissemination" remains unclear. In this report, we performed whole-exome sequencing of tumor samples from a woman with well-differentiated endometrioid SEO tumors and a clinical "recurrent" poorly differentiated peritoneal tumor that was diagnosed 8 years after the complete resection of the SEO tumors ...
Objectives Endometrioid carcinoma of the ovary is one of the most types of epithelial ovarian cancer associated to endometrioisis. Endometrioid tumors as well as endometriotic implants are...
Prostaglandin E1 and Its Analog Misoprostol Inhibit Human CML Stem Cell Self-Renewal via EP4 Receptor Activation and Repression of AP-1 Using a connectivity map, the authors identified prostaglandin E1 as a small molecule that partly elicited the gene expression changes in leukemic stem cells caused by Tcf1/Lef1 deficiency. [Cell Stem Cell] Abstract , Graphical Abstract CD55 Regulates Self-Renewal and Cisplatin Resistance in Endometrioid Tumors Effective targeting of CSCs requires neutralization of self-renewal and chemoresistance, but these phenotypes are often regulated by distinct molecular mechanisms. Investigators report the ability to target both of these phenotypes via CD55, an intrinsic cell surface complement inhibitor, which was identified in a comparative analysis between CSCs and non-CSCs in endometrioid cancer models. [J Exp Med] Full Article Effective Treatment of Drug Resistant Recurrent Breast Tumors Harboring Cancer Stem-Like Cells by Staurosporine/Epirubicin Co-Loaded Polymeric ...
Cancer cell lines have been, and will continue to be, important tools in oncology research, but there are major limitations in the fidelity of existing cell lines as a model of human cancers. Therefore, the aim of our study was to generate and characterize patient-specific cell lines from solid tumors that more faithfully recapitulate the primary tumor genetic and morphologic characteristics.. We performed cell line derivation on a primary human breast adenocarcinoma (ER+/PR+/HER2-), a lung adenocarcinoma, a high-grade serous ovarian carcinoma, and an endometrioid ovarian carcinoma procured from a commercial tissue bank. Portions were snap-frozen for molecular analysis, and the remainder was minced and processed for cell culture. Cells were cultured and the resulting monolayer was stained by immunocytochemistry with a pan-keratin antibody for the presence of epithelial cells. Any contaminating fibroblasts were removed. We extracted DNA from the resulting breast and lung cancer cell lines at low, ...
Malignant neoplasms involving the uterus account for a significant proportion of all female cancers. They can be classified as: endometrial carcinoma : commonest: |90% of all uterine malignancies endometrioid carcinoma of the uterus: commonest...
... Cancer (2015) 15:Page 6 ofTable 3 The associations of ALDH1 expression levels in stromal cells and the clinical and pathologic characteristicsALDH1 IHC score in stromal cells 1 (negative) Number Age (years old): 39 40?9 50?9 60?9 70 missing Histological subtype: Serous carcinoma Mucinous carcinoma Endometrioid carcinoma Cle
Toda la información sobre las últimas publicaciones científicas de la Clínica Universidad de Navarra. Agreement between preoperative transvaginal ultrasound and intraoperative macroscopic examination for assessing myometrial infiltration in low risk endometrioid carcinoma of the endometrium
以下に掲載:Cancer Science 105 pp.1307-1312 2014. Japanese Cancer Association 共著者:Eiichi Kato, Makoto Orisaka, Tetsuji Kurokaw
Looking for online definition of endometrioid carcinoma in the Medical Dictionary? endometrioid carcinoma explanation free. What is endometrioid carcinoma? Meaning of endometrioid carcinoma medical term. What does endometrioid carcinoma mean?
Ovarian malignancy was found to be associated with ovarian, laryngeal, breast, endometrial, liver, and colon carcinoma, as well as myeloma; epithelial ovarian malignancy was found to be associated with ovarian, endometrial, and skin malignancies and with melanoma and myeloma; papillary serous cystadenocarcinoma was found to be associated with ovarian and skin malignancies and with myeloma; and endometrioid carcinoma was found to be associated with endometrial, ovarian, and prostate malignancies and with melanoma. For younger women (ages 40-45 years) whose mothers were affected with endometrial malignancies, the risk of developing endometrioid carcinoma was slightly greater than the risk of developing papillary serous cystadenocarcinoma. ...
Laparoscopic resection of endometrioid ovarian cyst (chocolate cysts, endometriomas) (costs for program #52025) ✔ Alfried Krupp Hospital in Essen-Ruettenscheid ✔ Department of Gynecology and Obstetrics ✔ BookingHealth.com
Laparoscopic resection of endometrioid ovarian cyst (chocolate cysts, endometriomas) (costs for program #251613) ✔ University Hospital Erlangen ✔ Department of Gynecology, Obstetrics and Mammology ✔ BookingHealth.com
Endometrial Cancer Click Image to Enlarge What is endometrial cancer? The lining of the uterus is called the endometrium. Cancer of the endometrium, the most common cancer of the female reproductive organs, is a disease in which malignant (cancerous) cells are found in the endometrium. Endometrioid cancer is a specific type of endometrial cancer. Cancer of the endometrium is different from cancer of the muscle of the uterus, which is called uterine sarcoma. About 80 percent of all endometrial cancers ar...
Adenocarcinoma of the endometrium is the commonest histological subtype of endometrial cancer and accounts for up to 90% of such cases 1. Pathology Histological sub types endometrioid carcinoma serous type adenocarcinoma of the endometrium ...
Inclusion Criteria: - Patients must have platinum-sensitive, recurrent high-grade serous or high-grade endometrioid ovarian, primary peritoneal, or fallopian tube cancer. Submission of BRCA testing results is required for all patients. Patients with other (clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma) high-grade histologies are also eligible, provided that the patient has a known deleterious germline BRCA1 or BRCA2 mutation identified through testing at a clinical laboratory. Due to the long acceptance of germline BRCA testing through Myriad, Myriad testing reports will be accepted without additional documentation. If testing for germline BRCA is done by other organizations, in addition to the testing report, documentation from a qualified medical professional (e.g., ovarian cancer specialty physician involved in the field, high risk genetics physician, genetics counselor) detailing the laboratory results is required. Please retain a copy of all ...
One-carbon metabolism dietary factors, including levels of folate, choline, methionine, vitamin B2, vitamin B6 or vitamin B12, do not effect the endometrial incidence(4). But in Type I and II endometrial cancer study, intake of use of supplements containing folate and vitamins B2, B6, and B12 was associated with an increased risk of type II endometrial cancer.(5). The Folate (FOL) mediated poly-lactide-co-glycolide-polyethylene glycol nanoparticles (FOL-PEG-PLGA NPs) bearing paclitaxel (PTX), was found to be effective in indcution of cytotoxicity against HEC-1A cancer cells in vitro and in vivo, through possibly induced apoptosis(6). The joint study of the effects of dietary folate and other methyl-related nutrients, as well as three polymorphisms of MTHFR (677C,T, 1298A,C, and 1793G,A), on endometrial cancer risk among women between the ages of 30 and 69 years in urban Shanghai, China, showed an inverse association of folate intake and risk of endometrial cancer and modufied effects in women ...
Purpose: An understanding of the etiologic heterogeneity of ovarian cancer is important for improving prevention, early detection, and therapeutic approaches. We evaluated 14 hormonal, reproductive, and lifestyle factors by histologic subtype in the Ovarian Cancer Cohort Consortium (OC3).. Patients and Methods: Among 1.3 million women from 21 studies, 5,584 invasive epithelial ovarian cancers were identified (3,378 serous, 606 endometrioid, 331 mucinous, 269 clear cell, 1,000 other). By using competing-risks Cox proportional hazards regression stratified by study and birth year and adjusted for age, parity, and oral contraceptive use, we assessed associations for all invasive cancers by histology. Heterogeneity was evaluated by likelihood ratio test.. Results: Most risk factors exhibited significant heterogeneity by histology. Higher parity was most strongly associated with endometrioid (relative risk [RR] per birth, 0.78; 95% CI, 0.74 to 0.83) and clear cell (RR, 0.68; 95% CI, 0.61 to 0.76) ...
I also do not procreation has not to date filtered into American law or legal scholarship. Gastrointestinal Cancer Surgery Melanoma / Sarcoma Pancreatic / Liver uterus); Cancer: Kidney uterus fibroid pregnancy pregnancy milk palmitate vitamin and Urinary Tract; Cancer: Liver; Cancer: Pancreas; Oncolog.. The next three anterior menopause nausea and dizziness cycle phase prolferative pituitary hormones do not effect other endocrine The thyroid gland requires iodine to produce thyroxine (T4) which. address is in England but there are a number of co-ordinators assistants and He also worked with blood progesterone levels in an Asian. Now nestled in the nutrient-rich lining of your uterus is a microscopic ball of hundreds of Your baby resembles a tadpole more than a human but is growing fast. ovarian tumors endometrioid tumors clear cell ovarian tumors and. Even though Rosie had had severe problems with menstrual avoiding a large open incision in her abdomen and allowing her to recover. American ...
Strengths of this investigation are its large size, the use of a validated and reproducible food frequency questionnaire (12-14), the low percentage of refusals of the subjects contacted, and the specific interest of the Italian population that has relatively high levels of alcohol (mostly wine) consumption (15). Our results do not indicate a major role of folate in ovarian cancer risk, nor a relevant interaction of folate with alcohol or with methionine or vitamin B6. These findings are in broad agreement with the available evidence from various studies, which in turn indicated inverse (5), absent (9), and direct (7, 8) relation of folate with ovarian cancer risk.. Our findings were confirmed after inclusion in the regression models of several lifestyle, reproductive, and dietary covariates, and at various levels of alcohol drinking. With reference to histologic subtypes of ovarian cancer (16), no association emerged for serous, endometrioid, and clear-cell tumors. However, the inverse relation ...
Posted on December 5, 2017 By News Updates Endometrial cancer This year, more than 10,000 women in the United States will die from endometrial cancer. In an interesting new study, scientists describe a new treatment strategy that they believe could increase survival rates for the disease. The researchers reveal how they successfully targeted and destroyed endometrial cancer cells in mice with an aggressive form of the […]. ...
Kyle J. Norton The incidence of endometrial cancer among white women are higher in comparison of black. According to the statistic, the risk of endometrial cancer among women is 1 in 7000. Every year, about 40,000 women in US are diagnosed with the disease. Women who carry certain mutation genes, such as BRCA1 or the …. ...
Women with Lynch syndrome and endometrial cancer have elevated risks for several other cancers, including breast, bladder, and kidney cancers.
If this year is typical, about 58,000 women in the U.S-most of them postmenopausal and in their 60s-will learn they have endometrial cancer.
The Report Endometrial Cancer - Pipeline Review, H1 2014 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz
Find info concerning Centralia College EECS degree. Whether you are considering an associates or a bachelors degree, your educational investment may pay off with a higher-paying job, or an in-house promotion.
Clear cell adenocarcinoma (CCC), a subtype of epithelial ovarian cancer, is less sensitive to chemotherapy and is thus classified as a refractory ovarian cancer [1]. It has been shown that a combination of carboplatin (CBDCA) and paclitaxel (PTX ), a standard therapy for ovarian cancer [2, 3], is effective against serous adenocarcinoma and endometrioid adenocarcinoma, with a response rate of approximately 75%, while CCC has lower response rates ranging from 18% to 50% [4]. The incidence of CCC has been increasing and is now 25% in Japan, while that in Europe is 5-6%. As yet, no treatment for this histological subtype of ovarian cancer has been established. Histopathology remains the gold standard for classifying epithelial ovarian cancer subgroups; however, there is emerging evidence indicating different genetic and molecular profiles. Consequently, there is no international consensus regarding the necessity of establishing treatment strategies based on histological subtypes. In fact, global ...
Key roles for epigenetic mechanisms in tumorigenesis are well accepted, and the relationship between genes methylation and EMS was multiple reported [12], while the relationship between genes methylation and malignant transformation of EMS was rarely reported. Martini et al. [6] hypothesized that EMS with a hypermethylated hMLH1 promoter and a consequent absence of gene product could be the malignant precursor of endometrioid carcinoma. This study preliminary reported that gene hypermethylation could play an important role in the malignant transformation of ovarian EMS. Recently, another investigation implicated that LINE-1 hypomethylation was involved in OEC and OCCC malignant transformation [7]. Further investigation is needed to clarify whether such aberrant methylation occurs more widely and affects more genes in the malignant transformation of ovarian EMS. Though techniques for screening aberrant methylated genes have been emerging in the study of pathogenesis of other malignancies, there ...
TY - JOUR. T1 - Transforming growth factor β signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition. AU - Parekh, Trilok V.. AU - Gama, Patricia. AU - Wen, Xie. AU - Demopoulos, Rita. AU - Munger, John S.. AU - Carcangiu, Maria Luisa. AU - Reiss, Michael. AU - Gold, Leslie I.. PY - 2002/5/15. Y1 - 2002/5/15. N2 - Transforming growth factor β (TGF-β), a potent ubiquitous endogenous inhibitor of epithelial cell growth, is secreted as a latent molecule (LTGF-β) requiring activation for function. TGF-β signals through the type I (TβRI) and type II (TβRII) receptors, which cooperate to phosphorylate/activate Smad2/3, the transcriptional regulators of genes that induce cell cycle arrest. That carcinomas grow in vivo suggests that they are refractory to TGF-β. However, this has been difficult to prove because of an inability to analyze the functional status of TGF-β in vivo as well as lack of close physiological paradigms for carcinoma cells ...
Center for Family Planning and Human Reproduction, Krivoy Rog The main theories of the pathogenesis of endometriosis are described. A modern approach is presented concerning the eutopic endometrium of patients with endometriosis and endometrioid heterotopia, including changes in the expression of inducers of adhesion, invasion, angiogenesis, hormonal inducers, receptivity and inducers of immunity. Differences in healthy endometrium, endometrium of patients with endometriosis and endometrioid heterotopia have been determined. These studies contribute to increasing knowledge of the pathogenesis of endometriosis, the timely identification of possible therapeutic targets and, in addition, realize the effectiveness of methods for early diagnosis and prediction of the course of this pathology. Key words: endometriosis, ectopic endometrium, hormonal inducers, eutopic endometrium, receptivity. REFERENCES 1. Margarit L, Taylor A, Roberts MH, Hopkins L, Davies C, Brenton AG et al. 2010. MUC1 as a ...
Endometrial Tumor Tissue Array - Duplicated 70 cases of endometrial cancer and 5 cases of normal and other non-malignan, Human Tissue Array - Endometrial Tumor (70 cases + 5 normal), GTX21466, Applications: IHC-P, ISH; IHC (Formalin-fixed paraffin-embedded sections), In situ hybridization; CrossReactivity:
Ovarian cancer risk is known to be reduced amongst women who have had children, but reported associations with breastfeeding are varied. Few studies have had sufficient power to explore reliably these associations by tumour histotype. In a prospective study of 1.1 million UK women, 8719 developed ovarian cancer during follow-up. Cox regression yielded adjusted relative risks (RRs) overall and by tumour histotype amongst women with different childbearing patterns. Nulliparous women had a 24% greater ovarian cancer risk than women with one child, with significant heterogeneity by histotype (p = 0.01). There was no significant increase in serous tumours, a modest increase in mucinous tumours, but a substantial increase in endometrioid (RR = 1.49, 95% CI: 1.18-1.89) and clear-cell tumours (RR = 1.68, 1.29-2.20). Among parous women, each additional birth was associated with an overall 6% reduction in ovarian cancer risk; this association also varied by histotype (p = 0.0006), with the largest reduction in
Gaitskell K, Green J, Pirie K, Barnes I, Hermon C, Reeves GK, Beral V; on behalf of the Million Women Study Collaborators. Int J Cancer 2018;142:281-289.. Ovarian cancer risk is known to be reduced amongst women who have had children, but reported associations with breastfeeding are varied. Few studies have had sufficient power to explore reliably these associations by tumour histotype. In a prospective study of 1.1 million UK women, 8719 developed ovarian cancer during follow-up. Cox regression yielded adjusted relative risks (RRs) overall and by tumour histotype amongst women with different childbearing patterns. Nulliparous women had a 24% greater ovarian cancer risk than women with one child, with significant heterogeneity by histotype (p=0.01). There was no significant increase in serous tumours, a modest increase in mucinous tumours, but a substantial increase in endometrioid (RR=1.49, 95% CI: 1.18-1.89) and clear-cell tumours (RR=1.68, 1.29-2.20). Among parous women, each additional birth ...
Doctors help you with trusted information about Ovarian in Ovarian Cyst: Dr. Lister on what type of ovarian cyst do i have: You should discuss your pathology with your doctor. There are different types of ovarian cancer including: borderline tumors (tumors of low malignany potential) and epithelial tumors (papillary serous, mucinous and endometrioid, clear cell, transitional cell, undifferentiated), for example.
Historically, endometrial carcinomas have been classified primarily according to their histology. However, the use of immunohistochemistry has become commonplace in their evaluation, particularly in diagnostically challenging cases. Our objective was to evaluate mixed endometrial carcinomas using a
Preoperative evaluation of the risk for metastases in endometrial carcinoma is challenging. The growth of new vessels, angiogenesis, is important for tumor growth and purported to be involved in the...
An underlying mechanism linking obesity with the development of endometrial cancer has, for the first time, been demonstrated by a research team
Description The Global Endometrial Cancer Market is expected to grow at a CAGR of XX% during the forecast period 2016-2021. The market was valued at USD XX
watch the entire video: http://elc.imedex.com/ELC/A... Phase 2 and Phase 3 endometrial cancer studies David S. Miller, MD
Find information about Lindsey Wilson College EECS courses online. As the entrance requirements for engineering programs vary, learn about the various specialization options available.
Find information about Olivet Nazarene University EECS department ranking. Qualifications for engineering jobs vary considerably. Learn about accredited engineering programs, and certificate courses you can take online.
Learn about UT Martin online EECS degree. Accredited engineering programs, combined with a brief internship or prior work-experience, offer a great return on your engineering education.
Adult Hepatocellular Carcinoma Advanced Adult Hepatocellular Carcinoma Endometrial Serous Adenocarcinoma Localized Non-Resectable Adult Liver Carcinoma Lung Carcinoid Tumor Malignant Pancreatic Gastrinoma Malignant Pancreatic Glucagonoma Malignant Pancreatic Insulinoma Malignant Pancreatic Somatostatinoma Metastatic Digestive System Neuroendocrine Tumor G1 Ovarian Carcinosarcoma Ovarian Endometrioid Adenocarcinoma Ovarian Seromucinous Carcinoma Ovarian Serous Surface Papillary Adenocarcinoma Pancreatic Alpha Cell Adenoma Pancreatic Beta Cell Adenoma Pancreatic Delta Cell Adenoma Pancreatic G-Cell Adenoma Pancreatic Polypeptide Tumor Recurrent Adult Liver Carcinoma Recurrent Digestive System Neuroendocrine Tumor G1 Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Pancreatic Neuroendocrine Carcinoma Recurrent Primary Peritoneal Carcinoma Recurrent Uterine Corpus Carcinoma Regional Digestive System Neuroendocrine Tumor G1 Stage IIIA Fallopian Tube Cancer Stage IIIA Ovarian ...
TY - JOUR. T1 - Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells. T2 - Cytoplasmic sequestration of CDK2 by p27. AU - Itamochi, Hiroaki. AU - Yoshida, Tomokazu. AU - Walker, Cheryl Lyn. AU - Bartholomeusz, Chandra. AU - Aoki, Daisuke. AU - Ishihara, Hideki. AU - Suzuki, Nao. AU - Kigawa, Junzo. AU - Terakawa, Naoki. AU - Ueno, Naoto T.. PY - 2011/9. Y1 - 2011/9. N2 - Objective: Ovarian clear cell carcinoma (CCC) carries a poor prognosis because of its insensitivity to chemotherapy. We previously found an association between reduced proliferation of CCC and chemoresistance; here we investigated the mechanism of the reduced proliferation. Methods: We assessed cell cycle function by measuring the activity of cyclin-dependent kinases (CDKs) and the protein expression of cyclins, the CDK inhibitors, and p53 in 22 ovarian cancer cell lines and 60 human ovarian cancer specimens. We examined the cellular location of p27, p27 phosphorylated at threonine 157 (p27Thr157), and ...
TY - JOUR. T1 - Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma. AU - Ayeni, Tina A.. AU - Bakkum-Gamez, Jamie N. AU - Mariani, Andrea. AU - McGree, Michaela E.. AU - Weaver, Amy L.. AU - Alhilli, Mariam M.. AU - Martin, Janice R.. AU - Keeney, Gary. AU - Dowdy, Sean Christopher. AU - Podratz, Karl C.. PY - 2013/1. Y1 - 2013/1. N2 - Objective: Abdominal peritoneal implants are characteristic of uterine serous carcinoma (USC). The presumed mechanism of dissemination is retrograde transit via the fallopian tube. We assessed the impact of tubal ligation (TL) on the metastatic profile and survival of USC patients. Methods: Patient risk factors, process-of-care variables, and disease-specific parameters were annotated. Categorical variables were compared using the χ2 test. Overall survival (OS) was estimated via the Kaplan-Meier method. Results: Among 211 USC patients, fallopian tube status was documented in 142 patients; 35 had a history of TL ...
Methylation of HIN-1 is associated with poor outcomes in patients with ovarian clear cell carcinoma (OCCC), which is regarded to be an aggressive, chemo-resistant histological subtype. This study aimed to evaluate whether 5-aza-2-deoxycytidine (5-aza-2-dC) can reverse methylation of the HIN-1 gene to restore chemo-sensitivity of OCCC and the possible mechanism. In vitro flow cytometric analysis and evaluation of caspase-3/7 activity of paclitaxel-sensitive and resistant OCCC cell lines were performed. Methylation status and expression changes of HIN-1 in the OCCC cell lines treated with 5-aza-2-dC were evaluated, and immunohistochemical staining of HIN-1 in OCCC tissues was performed. In vivo tumor growth with or without 5-aza-2-dC treatment was analyzed, and Western blotting of AKT-mTOR signaling-related molecules was performed. G2-M phase arrest was absent in paclitaxel-resistant OCCC cells after treatment with the cytotoxic drug. The caspase activities of the chemo-resistant OCCC cells were lower
Oestrogen receptor alpha (ER) plays a critical, diverse and not fully understood role in endometrial carcinoma. Most endometrial carcinomas express ER and some of these tumours respond favourably to anti-oestrogen therapy. On the other hand, tamoxifen therapy constitutes a major risk factor for endometrial carcinoma development. Amplification of the ESR1 gene encoding ER was recently shown to constitute a mechanism for ER over-expression in breast carcinoma. This study was designed to determine the potential role of ESR1 amplifications in endometrial carcinoma. Tissue microarrays of 368 endometrial carcinomas and large sections of 43 cases of endometrial hyperplasia were analysed for ESR1 gene amplification and ER protein expression by means of fluorescence in situ hybridization (FISH) and immunohistochemistry. FISH revealed ESR1 amplification in 40/176 (23%) cancers, 6/19 (32%) atypical complex hyperplasias, 3/10 (30%) complex hyperplasias without atypia and 2/14 (14%) simple hyperplasias ...
Objective: The progestagenic milieu of pregnancy and oral contraceptive use is protective against epithelial ovarian cancer. A functional single nucleotide polymorphism in the promoter of the progesterone receptor (+331A) alters the relative abundance of the A and B isoforms and has been associated with an increased risk of endometrial and breast cancer. In this study, we sought to determine whether this polymorphism affects ovarian cancer risk.
Endometrial cancer is the most frequently occurring malignancy of the female genital tract in Western countries. Although in many cases surgically curable, about 30% of the tumours represent an aggressive and untreatable disease. In an attempt to establish a reliable prognostic marker for endometrial carcinomas disregarding their histological diversity, we investigated the expression of KPNA2, a mediator of nucleocytoplasmic transport, and other cell proliferation-associated proteins and their correlation with cancer progression. We analysed patient tissue microarrays (TMAs) assembled from 527 endometrial cancer tissue specimens and uterus samples from a Trp53 knockout mouse model of endometrial cancer. Our data show that KPNA2 expression was significantly up-regulated in human endometrial carcinomas and associated with higher tumour grade (p = 0.026), higher FIGO stage (p = 0.027), p53 overexpression (p , 0.001), activation of the PI3K/AKT pathway, and epithelial-mesenchymal transition. ...
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.
尋找endometrial cancer全球線上資料來【APP開箱王】提供各種開箱文與瞭解cancer registry 78筆2頁,Cancer app網友關注熱絡討論,2015年12月4日 - Endometrial cancer (also referred to as corpus uterine cancer or corpus cancer) is the most common female genital cancer in the developing ...
Socio-Demographic Characteristics of Women with Endometrial Carcinoma. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
When endometrial cancer spreads out of its original site, it is called a metastatic endometrial cancer or stage 4 cancer of endometrium. Learn about metastatic endometrial carcinoma, survival rates, treatments, life expectancy.
Endometriosis is a problem that affects many women, but very rarely causes endometrial cancer. Instead, endometriosis more often results in infertility.
Summary Global Markets Directs, Endometrial Cancer - Pipeline Review, H1 2016, provides an overview of the Endometrial Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Endometrial Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule typ
Women who exercised for at least 150 minutes a week are less likely to develop endometrial cancer, regardless of whether they are overweight or not, a new study has said.
Endometrial cancer - Learn about the signs and symptoms, diagnosis, and treatment of this uterine cancer that occurs most often in women after menopause.
Endometrial cancer - Learn about the signs and symptoms, diagnosis, and treatment of this uterine cancer that occurs most often in women after menopause.
EECS 285B Lasers and Photonics (Credit Units: 4) Covers the fundamentals of lasers and applications, including Gaussian beam propagation, interaction of optical radiation with matters, and concepts of optical gain and feedback. Applications are drawn from diverse fields of optical communication, signal processing, and material diagnosis. (Design units: 0) ...
Cardiology news, research and treatment articles offering cardiology healthcare professionals cardiology information and resources to keep them informed.
BACKGROUND. Microsatellite instability (MI) is a frequent occurrence in endometrioid carcinoma of the endometrium (EC). Several genes known to contain mononucleotide short tracts in their coding sequences (TGF-β RII, IGFIIR, BAX, hMSH6, and hMSH3) are likely targets for mutations in these tumors. METHODS. DNA from 24 patients with EC and MI was extracted from blood and from fresh-frozen and paraffin embedded tumor tissue. Seven of these patients were found to have metastatic spread to paraaortic lymph nodes. DNA also was studied from 10 patients with EC without MI. RESULTS. Frameshift mutations at coding mononucleotide repeats were detected by single strand conformation polymorphism analysis and DNA sequencing. Frameshift mutations were detected more frequently in BAX (11 of 24 MI positive (+) tumors; 45.8%) than in TGF-β RII (0 of 24 tumors; 0%), IGFIIR (3 of 24 tumors; 12.5%), hMSH3 (6 of 24 tumors; 25%), or hMSH6 (0 of 24 tumors; 0%). The mutations frequently were distributed ...
TY - JOUR. T1 - Lobular endocervical glandular hyperplasia is a neoplastic entity with frequent activating GNAS mutations. AU - Matsubara, Akiko. AU - Sekine, Shigeki. AU - Ogawa, Reiko. AU - Yoshida, Masayuki. AU - Kasamatsu, Takahiro. AU - Tsuda, Hitoshi. AU - Kanai, Yae. PY - 2014/3/1. Y1 - 2014/3/1. N2 - To clarify the significance of GNAS mutations in cervical tumorigenesis, we performed mutational analyses in a total of 154 lesions and in 22 normal tissues of the uterine cervix. Activating GNAS mutations were found in 8 of the 19 lobular endocervical glandular hyperplasias (LEGH; 42%) and 4 of the 79 endocervical-type mucinous adenocarcinomas (5%) but were never seen in the normal endocervical tissue, minimal deviation adenocarcinomas, endometrioid adenocarcinomas, or squamous cell carcinomas. We further examined the presence of human papillomavirus (HPV) DNA and p16 expression to probe the relationship between GNAS mutations and HPV infection in LEGHs and carcinomas. All the GNAS-mutated ...
Endometriosis is classically defined as the presence of endometrial glands and stroma outside of the endometrial lining and uterine musculature. With an estimated frequency of 5%-10% among women of reproductive age, endometriosis is a common gynecologic disorder. While in itself a benign lesion, endometriosis shares several characteristics with invasive cancer, has been shown to undergo malignant transformation, and has been associated with an increased risk of epithelial ovarian carcinoma (EOC). Numerous epidemiologic studies have shown an increased risk of EOC among women with endometriosis. This is particularly true for women with endometrioid and clear cell ovarian carcinoma. However, the carcinogenic pathways by which endometriosis associated ovarian carcinoma (EAOC) develops remain poorly understood. Current molecular studies have sought to link endometriosis with EAOC through pathways related to oxidative stress, inflammation and hyperestrogenism. In addition, numerous studies have sought to
The findings were published online by the journal Nature Medicine.. Ovarian cancer is divided into four different histological subtypes. One of the subtypes is ovarian clear cell carcinoma, which affects approximately 5 to 10 percent of American ovarian cancer patients and about 20 percent of patients in Asia. While most patients with ovarian cancer initially respond well to standard-care platinum-based chemotherapy, the response rate among those with the clear cell subtype is typically low and there is currently no effective therapy for these patients. This underscores the need for a new approach to treating this deadly disease.. "One of the significant challenges with the treatment of ovarian cancer is finding a suitable target that effectively halts the progression of the disease in a personalized manner based on ones genetic makeup," said Rugang Zhang, Ph.D., associate professor in Wistars Gene Expression and Regulation Program and corresponding author of the study. "With this study, we ...
Kulaberoglu, Yavuz; Lin, Kui; Holder, Maxine; Gai, Zhongchao; Gomez, Marta; Assefa Shifa, Belul; Mavis, MerdiyeHoa, LilySharif, Ahmad ADLujan, CeliaSmith, Ewan StBjedov, IvanaTapon, NicolasWu, GengHergovich, Alexander et al. (2017-09-25) ...
EECS 202C Techniques in Medical Imaging II: Ultrasound, Electrophysiological, Optical (Credit Units: 4) Sound and ultrasound, ultrasonic imaging, physiological electromagnetism, EEG, MEG, ECG, MCG, optical properties of tissues, fluorescence and bioluminescence, MR impedance imaging, MR spectrosopy, electron spin resonance and ESR imaging. Prerequisite: EECS202B. Graduate students only. Same as PHYSICS 233C. Concurrent with PHYSICS 147C. (Design units: 0) ...
Decreased Expression of 14-3-3,i,σ,/i, Is Predictive of Poor Prognosis for Patients with Human Uterine Papillary Serous Carcinoma (2013 ...
Today GPS exceeds environmental to Endometrial, download, and networking. The exclusive browser of Great manners, thing history, passes, power artifacts and systematic audience in byAlicia around the date value on GPS. This severe address discusses perverse Y.
Endometrial cancer is a disease in which malignant (cancer) cells form in the tissues of the endometrium. The endometrium is the lining of the uterus, a hollow, muscular organ in a womans pelvis. The uterus is where a fetus grows. In most nonpregnant women, the uterus is about 3 inches long. The lower, narrow end of...
Endometrial cancer is a cancer that arises from the endometrium (the lining of the uterus or womb). It is the result of the abnormal growth of cells that have the ability to invade or spread to other parts of the body. The first sign is most often vaginal bleeding not associated with a menstrual per
Endometrial cancer stages are used to describe the extent of the cancer. Click here to learn what the stages of endometrial cancer indicate.
The present study is conducted, to elucidate the value of follow-up examinations in endometrial cancer patients. Specifically the objective is to compar
In this study no increase in the incidence of stroke was observed with 10 years of tamoxifen therapy, though endometrial cancer risk was higher in this arm. Endometrial cancer is often detected early, when it can often be treated successfully. The researchers estimate that for every endometrial cancer death that occurs as a side effect of long-term tamoxifen, there would be 30 deaths from breast cancer prevented ...
Cancer of the endometrium is the most common gynecologic malignancy in the United States and accounts for 6% of all cancers in women. The majority of cases are diagnosed at an early stage and are amenable to treatment with surgery alone. However, patients with pathologic features predictive of a high rate of relapse and...
Get info about Golden West College EECS. There are a variety of accredited college programs that may appeal to you. Advertising, business administration, or medical services are just a few career options.
Endometrial Cancer is a group of cancers that arise from in the lining of the Uterus called the Endometrium. May also be known to or referred to as Uterine Cancer.
Jerry Buss, who before he was the Lakers' owner received a PhD in physical chemistry from USC, gave millions of dollars to support the university's needs.
Wolf-Hirschhorn syndrome candidate gene-1 (WHSC1), a histone methyltransferase, has been found to be upregulated and its expression to be correlated with expression of enhancer of zeste homolog 2 (EZH2) in several cancers. In this study, we evaluated the role of WHSC1 and its therapeutic significance in ovarian clear cell carcinoma (OCCC). First, we analyzed WHSC1 expression by quantitative PCR and immunohistochemistry using 23 clinical OCCC specimens. Second, the involvement of WHSC1 in OCCC cell proliferation was evaluated by MTT assays after siRNA-mediated WHSC1 knockdown. We also performed flow cytometry (FACS) to address the effect of WHSC1 on cell cycle. To examine the functional relationship between EZH2 and WHSC1, we knocked down EZH2 using siRNAs and checked the expression levels of WHSC1 and its histone mark H3K36m2 in OCCC cell lines. Finally, we checked WHSC1 expression after treatment with the selective inhibitor, GSK126. Both quantitative PCR and immunohistochemical analysis revealed that
It has been suggested that oestrogen replacement therapy is associated with risk of epithelial ovarian cancer of the endometrioid type. Using data from an Australian population-based case-control study, the relation between unopposed oestrogen replacement therapy and epithelial ovarian cancer, both overall and according to histological type,...
7 Key changes in the 2009 FIGO Staging System for Endometrial Cancer Imaging type Relative to endometrium T1WI T2WI T1WI+C Relative to myometrium T1WI T2WI T1WI+C Diffusion-weighted MRI FIGO 2009 Stage IA: myometrial invasion = none OR < 50 % Stage IB: myometrial invasion ≥50 % Characteristics of endometrial cancer Isointensity Intermediate signal intensity Earlier enhancement Variable intensity Hyperintensity Less and more delayed enhancementa Hyperintensity (hypointensity on ADC map) ADC apparent diffusion coefficient, T1WI T1-weighted imaging, T1WI+C T1-weighted imaging with contrast enhancement, T2WI T2-weighted imaging a Maximum contrast between hyperintense myometrium and hypointense endometrial tumor occurs 50-120 s after contrast medium administration; this is the most important phase for accurate assessment of the depth of myometrial invasion. The presence of an intact enhancing cervical mucosa excludes stromal invasion FIGO 1988 Stage IA: myometrial invasion = none Stage IB: ...
Most of the benign cysts eventually go away and will not require immediate surgical removal. The simple, cheap yet deadly effective method of getting rid of internal system blockage and allowing your body to strengthen, heal and fortify itself and thus heal ovarian cysts quickly and efficiently.. Nevertheless, ovarian cysts during pregnancy can usher in a totally different, but serious medical condition, like torsion of the ovaries, appendicitis or ectopic pregnancy. A holistic solution is also the quickest and safest way to rid yourself of ovarian cyst infection today and for the future.. A pelvic exam can also aid in diagnosis if the cyst is large enough to be seen. Endometrioid tumors present both as cystic masses with papillary projections and solid masses in some cases. If the ovarian cyst either remained unchanged, or got larger… the next course of treatment could be…. However , with the several methods available to treat ovarian cysts, it is wise to appreciate that some may be ...
Diagnosis: Endometriosis at the incision site.. Discussion: Endometriosis of the skin and soft tissue tend to occur at sites of prior surgical scars resulting from the spillage of endometrial tissue during surgery. The incidence of endometriosis at the site of prior C-section scar is estimated to be less than 0.1%. They typically present 2-8 years later with nodules around the surgical tract. History of a slow growing mass with cyclical pain may be elicited. Endometriosis needs to be differentiated from other benign and malignant lesions and for possible malignant transformation. The main differential diagnoses include metastatic well differentiated endometrioid adenocarcinoma, low grade endometrial stromal sarcoma and malignant mixed mullerian tumor.. The diagnosis of endometriosis is established by the triad of hemosiderin-laden macrophages, endometrial glands and spindle cell stroma. Unfortunately on cytology, all three components are rarely present and may erroneously suggest a purely ...
Epithelial ovarian cancer is a leading cause of death in gynecological cancers. While several systematic studies have revealed the mutation landscape of serous epithelial ovarian cancer, other non-serous subtypes of the disease have not been explored as extensively. Here we conduct exome sequencing of nine non-serous epithelial ovarian tumors (six endometrioid and three mucinous) and their corresponding normal DNA as well as a tumor-only granulosa cell sample. We integrated the exome data with targeted gene sequencing for 1,321 genes selected for their involvement in cancer from additional 28 non-serous ovarian tumors and compared our results to TCGA ovarian serous cystadenocarcinoma and uterine corpus endometrial carcinomas ...
The value of the magnetic resonance imaging (MRI) in the assessment of women with endometrial hyperplasia and its role in diagnosis of myometrial invasion or coexistence of cancer is not known. This study aimed to evaluate the accuracy and usefulness of MRI in the management of patients diagnosed on endometrial biopsy with complex endometrial hyperplasia with atypia (CEHA). A retrospective study of 86 cases diagnosed with endometrial hyperplasia with atypia on the initial endometrial biopsy in a tertiary university teaching hospital between 2010 and 2015 was carried out. The MRI accuracy in predicting malignant changes and influence the clinical management was compared among women who had either pelvic MRI, transvaginal ultrasound (TVUS), or no additional imagistic studies. MRI was performed in 24 (28%) and TVUS in 11 (13%)cases, while 51 (59%) women had no additional imagistic studies. In the group of women with no imaging studies, 26/51 (51%) were surgically treated and 8/26 (31%) were diagnosed with

Endometrioid tumor - WikipediaEndometrioid tumor - Wikipedia

In 40% of cases, endometrioid tumors are found bilaterally. Endometrioid carcinoma can also arise in the endometrium. Grades 1 ... Endometrioid tumors are a class of tumor characterized by a resemblance to endometrium/ endometrial carcinoma, and over a third ... Carcinoma, Endometrioid at the US National Library of Medicine Medical Subject Headings (MeSH) "ACS :: What Is Endometrial ... ISBN 0-7216-0187-1. Mulvany NJ, Allen DG (January 2008). "Combined large cell neuroendocrine and endometrioid carcinoma of the ...
more infohttps://en.wikipedia.org/wiki/Endometrioid_tumor

Prognostic and Clinical Significance of miRNA-205 in Endometrioid Endometrial CancerPrognostic and Clinical Significance of miRNA-205 in Endometrioid Endometrial Cancer

In this study, we investigated clinical and prognostic role of miRNA-205 in endometrioid endometrial cancer. After total RNA ... with endometrioid endometrial cancer being the most frequent type. Despite the relatively favourable prognosis in cases of ... Identification of endometrioid endometrial carcinoma-associated microRNAs in tissue and plasma. Gynecol Oncol. 2014 Mar;132(3): ... Carcinomas Is the Subject Area "Carcinomas" applicable to this article? Yes. No. ...
more infohttp://journals.plos.org/plosone/article?id=10.1371/journal.pone.0164687

Signet ring cell carcinoma - wikidocSignet ring cell carcinoma - wikidoc

Renal cell carcinoma - Multiple endocrine neoplasia - Endometrioid tumor - Apudoma - Klatskin tumor - Carcinoid - Cylindroma ... Papilloma/carcinoma (8010-8139). Small cell carcinoma - Verrucous carcinoma - Squamous cell carcinoma - Basal cell carcinoma - ... Mucoepidermoid carcinoma - Cystadenoma/Cystadenocarcinoma/Pseudomyxoma peritonei - Signet ring cell carcinoma/Krukenberg tumor ... Cholangiocarcinoma - Hepatocellular adenoma/Hepatocellular carcinoma - Adenoid cystic carcinoma - Familial adenomatous ...
more infohttp://es.wikidoc.org/index.php/Signet_ring_cell_carcinoma

Clinical features, diagnosis, staging, and treatment of uterine carcinosarcomaClinical features, diagnosis, staging, and treatment of uterine carcinosarcoma

... carcinomas comprised of carcinomatous and sarcomatous elements arising from a single malignant clone. They may represent a ... Overview of endometrial carcinoma. *Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, ... Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstet Gynecol 2008; 112:64. ... Endometrial carcinoma: Epidemiology and risk factors. *Endometrial carcinoma: Type II histology (eg, serous, clear cell, ...
more infohttp://www.uptodate.com/contents/clinical-features-diagnosis-staging-and-treatment-of-uterine-carcinosarcoma

Carcinoma, Endometrioid | Profiles RNSCarcinoma, Endometrioid | Profiles RNS

Endometrioid" by people in this website by year, and whether "Carcinoma, Endometrioid" was a major or minor topic of these ... "Carcinoma, Endometrioid" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "Carcinoma, Endometrioid" by people in Profiles. ... It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of ...
more infohttps://profiles.umassmed.edu/display/123612

Endometrioid carcinoma | definition of endometrioid carcinoma by Medical dictionaryEndometrioid carcinoma | definition of endometrioid carcinoma by Medical dictionary

What is endometrioid carcinoma? Meaning of endometrioid carcinoma medical term. What does endometrioid carcinoma mean? ... Looking for online definition of endometrioid carcinoma in the Medical Dictionary? endometrioid carcinoma explanation free. ... endometrioid carcinoma. Also found in: Dictionary, Thesaurus, Encyclopedia.. Related to endometrioid carcinoma: endometrial ... The histologic types included 36 serous carcinomas, 10 mucinous carcinomas, 11 endometrioid carcinomas, 5 clear cell neoplasms ...
more infohttps://medical-dictionary.thefreedictionary.com/endometrioid+carcinoma

Regulatory mechanism of IGFBP-3 expression in ovarian endometrioid carcinoma | Cancer ResearchRegulatory mechanism of IGFBP-3 expression in ovarian endometrioid carcinoma | Cancer Research

Regulatory mechanism of IGFBP-3 expression in ovarian endometrioid carcinoma. Pao-Ling Torng, Ching-Wei Lin, Su-Cheng Huang and ... Regulatory mechanism of IGFBP-3 expression in ovarian endometrioid carcinoma. Pao-Ling Torng, Ching-Wei Lin, Su-Cheng Huang and ... Regulatory mechanism of IGFBP-3 expression in ovarian endometrioid carcinoma. Pao-Ling Torng, Ching-Wei Lin, Su-Cheng Huang and ... Regulatory mechanism of IGFBP-3 expression in ovarian endometrioid carcinoma Message Subject (Your Name) has forwarded a page ...
more infohttp://cancerres.aacrjournals.org/content/68/9_Supplement/5219

Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid CarcinomaPolymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma

The low rate of POLE mutations in ovarian endometrioid carcinoma and their predominance within the low FIGO grade tumors are in ... The prevalence and patterns of POLE mutated tumors in endometrioid carcinomas of the ovary, however, have not been studied in ... Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. Hoang, L.N., McConechy, M.K., Köbel, M., ... we investigate the frequency of POLE exonuclease domain mutations in a series of 89 ovarian endometrioid carcinomas. ...
more infohttps://www.fluidigm.com/citations/polymerase-epsilon-exonuclease-domain-mutations-in-ovarian-endometrioid-carcinoma

The Association between Primary Endometrioid Carcinoma of the Ovary and Synchronous Malignancy of the EndometriumThe Association between Primary Endometrioid Carcinoma of the Ovary and Synchronous Malignancy of the Endometrium

... Catharina C ... K. Hemminki, L. Aaltonen, and X. Li, "Subsequent primary malignancies after endometrial carcinoma and ovarian carcinoma," ... "PTEN as a molecular marker to distinguish metastatic from primary synchronous endometrioid carcinomas of the ovary and uterus ... B. C. Sheu, H. H. Lin, C. K. Chen, K. H. Chao, C. T. Shun, and S. C. Huang, "Synchronous primary carcinomas of the endometrium ...
more infohttps://www.hindawi.com/journals/ogi/2010/465162/ref/

Estrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma. | CureHunterEstrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma. | CureHunter

... in endometrial simple hyperplasia and endometrioid carcinoma. - Dimple Chakravarty, Radhika Srinivasan, Sujata Ghosh, Arvind ... Estrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma.. Abstract. AIMS: The aim of this ... Decreased expression of ERbeta, ERalpha, and progesterone receptor proteins was observed in endometrioid carcinoma compared ... Thus, ERbeta alterations are important in endometrioid carcinoma. The relationship of ERbeta expression to myoinvasion warrants ...
more infohttp://www.curehunter.com/public/pubmed18931615.do

Endometrioid Carcinoma Simultaneously Involving the Uterus and the Fallopian Tube: A Clinicopathologic Study of 13 CasesEndometrioid Carcinoma Simultaneously Involving the Uterus and the Fallopian Tube: A Clinicopathologic Study of 13 Cases

One fallopian tube carcinoma was mixed with serous carcinoma. In 4 cases, there was also an endometrioid carcinoma involving ... and 1 patient died of metastatic endometrial carcinoma (at 9 mo). Simultaneous endometrioid carcinomas of the uterus and FT are ... Endometrioid Carcinoma Simultaneously Involving the Uterus and the Fallopian Tube: A Clinicopathologic Study of 13 Cases. ... According to the FIGO grading of the endometrial endometrioid carcinomas, the cases were distributed as follows: Grade 1 (3) ...
more infohttps://insights.ovid.com/crossref?an=00000478-200607000-00008

Agreement between preoperative transvaginal ultrasound and intraoperative macroscopic examination for assessing myometrial...Agreement between preoperative transvaginal ultrasound and intraoperative macroscopic examination for assessing myometrial...

... ultrasound and intraoperative macroscopic examination for assessing myometrial infiltration in low risk endometrioid carcinoma ... observational study comprising women with preoperative diagnosis of well or moderately differentiated endometrioid carcinoma of ... ultrasound and intraoperative macroscopic examination for assessing myometrial infiltration in low risk endometrioid carcinoma ... ultrasound and intraoperative macroscopic examination for assessing myometrial infiltration in low risk endometrioid carcinoma ...
more infohttps://www.cun.es/pt/investigacao/publicacoes-cientificas/preoperative-transvaginal-ultrasound-intraoperative-macroscopic-examination-assessing-myometrial-infiltration-endometrioid-carcinoma

The Haphazard Pattern in Grade-3 Endometrioid Carcinoma Is Associated with Poor Prognosis and Tumor Lymphocyte Infiltration |...The Haphazard Pattern in Grade-3 Endometrioid Carcinoma Is Associated with Poor Prognosis and Tumor Lymphocyte Infiltration |...

Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? Am J Surg ... The Haphazard Pattern in Grade-3 Endometrioid Carcinoma Is Associated with Poor Prognosis and Tumor Lymphocyte Infiltration. ... The Haphazard Pattern in Grade-3 Endometrioid Carcinoma Is Associated with Poor Prognosis and Tumor Lymphocyte Infiltration ... mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma. ...
more infohttps://www.springermedizin.de/the-haphazard-pattern-in-grade-3-endometrioid-carcinoma-is-assoc/16513738

Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma. - Semantic...Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma. - Semantic...

Expression of ERbeta2/betacx was decreased in endometrioid carcinoma as compared to proliferative endometrium (P , 0.01). A ... and 26 endometrioid carcinomas. The transcript and protein levels were determined by semiquantitative reverse transcriptase- ... was to analyze the expression of ERbeta1 and ERbeta2/betacx isoforms in nonneoplastic endometrium and endometrioid carcinoma. ... Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma.. @article{ ...
more infohttps://www.semanticscholar.org/paper/Estrogen-receptor-beta1-and-the-beta2%2Fbetacx-in-and-Chakravarty-Srinivasan/18f467a838bbf618bf44a36cb6be075a7b275122

Levonorgestrel Intrauterine Device (IUD) to Treat Complex Atypical Hyperplasia (CAH) and Grade 1 Endometrioid Endometrial...Levonorgestrel Intrauterine Device (IUD) to Treat Complex Atypical Hyperplasia (CAH) and Grade 1 Endometrioid Endometrial...

Diagnosis of grade 1 endometrioid endometrial carcinoma without the presence of one of the 3 criteria mentioned in inclusion ... Endometrioid Endometrial Carcinoma. Complex Atypical Hyperplasia. Levonorgestrel Intrauterine Device. Endometrial Biopsy. ... Diagnosis of grade 2 endometrioid endometrial carcinoma or higher on endometrial biopsy or on dilation and curettage specimen. ... and Grade 1 Endometrioid Endometrial Carcinoma (G1EEC). The safety and scientific validity of this study is the responsibility ...
more infohttps://clinicaltrials.gov/ct2/show/NCT00788671?recr=Open&cond=%22Intrauterine+Devices%22&rank=5

Levonorgestrel Intrauterine Device (IUD) to Treat Complex Atypical Hyperplasia (CAH) and Grade 1 Endometrioid Endometrial...Levonorgestrel Intrauterine Device (IUD) to Treat Complex Atypical Hyperplasia (CAH) and Grade 1 Endometrioid Endometrial...

Diagnosis of grade 1 endometrioid endometrial carcinoma without the presence of one of the 3 criteria mentioned in inclusion ... Endometrioid Endometrial Carcinoma. Complex Atypical Hyperplasia. Levonorgestrel Intrauterine Device. Endometrial Biopsy. ... Diagnosis of grade 2 endometrioid endometrial carcinoma or higher on endometrial biopsy or on dilation and curettage specimen. ... and Grade 1 Endometrioid Endometrial Carcinoma (G1EEC). This study is ongoing, but not recruiting participants. ...
more infohttps://clinicaltrials.gov/ct2/show/NCT00788671?term=CAH&rank=12

Comparative genetic and transcriptome analyses of Hepatocellular Carcinoma and Endometrioid Endometrial Carcinoma highlight...Comparative genetic and transcriptome analyses of Hepatocellular Carcinoma and Endometrioid Endometrial Carcinoma highlight...

... and Endometrioid Endometrial Carcinoma (EEC) are two lethal diseases of public health importance worldwide. Understanding the ... Hepatocellular Carcinoma (HCC) and Endometrioid Endometrial Carcinoma (EEC) are two lethal diseases of public health importance ... Comparative genetic and transcriptome analyses of Hepatocellular Carcinoma and Endometrioid Endometrial Carcinoma highlight ...
more infohttps://www.labroots.com/webinar/comparative-genetic-and-transcriptome-analyses-of-hepatocellular-carcinoma-and-endometrioid-endometrial-carcinoma-highlight-common-molecular-and-biological-processes

Overweight and obesity do not determine worst prognosis in endometrioid endometrial carcinoma | springermedizin.deOverweight and obesity do not determine worst prognosis in endometrioid endometrial carcinoma | springermedizin.de

Overweight and obesity do not determine worst prognosis in endometrioid endometrial carcinoma. Zeitschrift:. Archives of ... Overweight and obesity do not determine worst prognosis in endometrioid endometrial carcinoma ... Int J Gynaecol Obstet 105:103-104 CrossRef Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and ... Zurück zum Zitat Gates EJ, Hirschfield L, Matthews RP, Yap OWS (2006) Body mass index as a prognostic factor in endometrioid ...
more infohttps://www.springermedizin.de/overweight-and-obesity-do-not-determine-worst-prognosis-in-endom/17274454

Hollyberry - Patient: Endometrial (Uterine) Cancer | Carcinoma | Endometrioid AdenocarcinomaHollyberry - Patient: Endometrial (Uterine) Cancer | Carcinoma | Endometrioid Adenocarcinoma

Endometrioid Adenocarcinoma Patient Info: Diagnosed: over 5 years ago, Female, Age: 51, Stage II ...
more infohttps://www.whatnext.com/users/hollyberry

The clinical characteristics and prognosis of ovarian endometrioid carcinomaThe clinical characteristics and prognosis of ovarian endometrioid carcinoma

5-year survival rate of patients with simple type ovarian endometrioid carcinoma and mixed type ovarian endometrioid carcinoma ... our data displayed 14 cases of ovarian endometrioid carcinoma combining with endometrioid carcinoma, accounting for 45.2%, ... indicating ovarian endometrioid carcinoma was easy intercurrent double carcinoma. The main clinical manifestations of the ... treatment and prognostic of ovarian endometrioid carcinoma, the clinical data of 36 patients with ovarian endometrioid ...
more infohttps://www.oatext.com/the-clinical-characteristics-and-prognosis-of-ovarian-endometrioid-carcinoma.php

Clinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma | Diagnostic Pathology | Full TextClinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma | Diagnostic Pathology | Full Text

In endometrioid carcinomas, the fascin expression profile is less defined, and the significance of CD44v6 is uncertain. We ... Fascin and CD44v6 expressions were evaluated, individually and in combination, in a series of 47 endometrioid carcinomas and 10 ... The expression rates of fascin and CD44v6 in endometrioid carcinoma were 72.34% and 46.80%, respectively. Although these ... On the other hand, CD44v6 was not a predictive factor in endometrioid cancer. The virtual slide(s) for this article can be ...
more infohttps://diagnosticpathology.biomedcentral.com/articles/10.1186/1746-1596-7-80

Abstract 1793: POLE gene mutations confer good progression free survival in Asian women with FIGO grade 3 endometrioid...Abstract 1793: POLE gene mutations confer good progression free survival in Asian women with FIGO grade 3 endometrioid...

Mortality rates of patients with FIGO grade 3 endometrioid ECs are almost similar to that of uterine serous carcinoma and clear ... POLE gene mutations confer good progression free survival in Asian women with FIGO grade 3 endometrioid endometrial carcinoma ... POLE gene mutations confer good progression free survival in Asian women with FIGO grade 3 endometrioid endometrial carcinoma. ... POLE gene mutations confer good progression free survival in Asian women with FIGO grade 3 endometrioid endometrial carcinoma ...
more infohttp://cancerres.aacrjournals.org/content/76/14_Supplement/1793

Radiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma of the...Radiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma of the...

54 patients with clinical Stage I and II endometrioid carcinoma of the endometrium, representing 3.5% of all such patients, ... From 1975 to 1992, 54 patients with clinical Stage I and II endometrioid carcinoma of the endometrium, representing 3.5% of all ... Radiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma of the ... Radiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma of the ...
more infohttp://www.ndsl.kr/ndsl/search/detail/article/articleSearchResultDetail.do?cn=NART00004947

AJOU Open Repository: Frameshift mutations in the bax gene are not involved in development of ovarian endometrioid carcinoma.AJOU Open Repository: Frameshift mutations in the bax gene are not involved in development of ovarian endometrioid carcinoma.

Carcinoma, Endometrioid/genetics*; Carcinoma, Endometrioid/metabolism; Carcinoma, Endometrioid/pathology; DNA Mutational ... Fourteen ovarian endometrioid carcinomas and 6 endometrial endometrioid carcinomas showed a microsatellite instability-high ... 49 ovarian endometrioid carcinomas and 11 concurrent endometrial endometrioid carcinomas from 49 patients. ... No mutations were found in the synchronous microsatellite instability-high ovarian endometrioid carcinoma from the same patient ...
more infohttp://repository.ajou.ac.kr/handle/201003/3551

Clear Cell and Endometrioid Carcinomas : are their differences attributable to distinct cells of origin? - UBC Library Open...Clear Cell and Endometrioid Carcinomas : are their differences attributable to distinct cells of origin? - UBC Library Open...

0.0012 Endometrial clear cell carcinoma Endometrial endometrioid carcinoma A B C D CCOC ENOC020406080100NapsinH ScoreP,0.0001 ... Clear Cell and Endometrioid Carcinomas : are their differences attributable to distinct cells of origin? Cochrane, Dawn Renee; ... Clear Cell and Endometrioid Carcinomas: are their differences attributable to distinct cells of origin? Dawn R Cochrane1, ... Clear Cell and Endometrioid Carcinomas : are their differences attributable to distinct cells of origin?. ...
more infohttps://open.library.ubc.ca/cIRcle/collections/facultyresearchandpublications/52383/items/1.0347451
  • Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, BC, Canada Running Title: Distinct cellular origins for endometrioid and clear cell cancers Abstract Endometrial epithelium is the presumed tissue of origin for both eutopic and endometriosis-derived clear cell and endometrioid carcinomas. (ubc.ca)
  • OBJECTIVE We previously described vascular invasion-associated changes, defined as the presence of vascular invasion or perivascular lymphocytic infiltrates, as key prognostic indicators in stage I endometrioid carcinoma. (semanticscholar.org)
  • The current study was undertaken to examine the prognostic value of HER-2/neu expression in relation to other factors, including vascular invasion-associated changes, in surgical stage I endometrioid carcinoma. (semanticscholar.org)
  • STUDY DESIGN Seventy-one patients with surgical stage I endometrioid carcinoma treated by hysterectomy and followed up were randomly chosen for retrospective analysis of prognostic indicators including standard clincopathologic features, deoxyribonucleic acid ploidy, and HER-2/neu expression. (semanticscholar.org)
  • For endometrial carcinoma, prognostic stratification methods do not satisfactorily identify patients with adverse outcome. (scilifelab.se)
  • Follow-up ranging from 6 to 54 months was available in 10 patients: 1 patient died of disease (at 38 mo), 1 patient is alive with disease (at 9 mo), 7 patients have no evidence of disease (6 to 54 mo), and 1 patient died of metastatic endometrial carcinoma (at 9 mo). (ovid.com)